Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625671 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
A Phase 1 study of Systemic Lupus Erythematosus (SLE), sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
- 4
- Study locations
NCT06625671 is a Phase 1 study of Systemic Lupus Erythematosus (SLE) that is actively recruiting participants, run by DualityBio. The registered enrollment target is 148 participants, below the 1,054-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06625671, a Phase 1 study of Systemic Lupus Erythematosus (SLE), is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisone
- DRUG DB-2304
Study Locations (4)
Texas
- US04-0 - Irving
- US02-0 - San Antonio
Florida
- US03-0 - Clearwater
Victoria
- Site AUS01-0 - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625671
The ClinicalTrials.gov registry entry for NCT06625671 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,054-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (86% lower). The listed sponsor is DualityBio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06625671 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Florida, Victoria.
Frequently Asked Questions
What is clinical trial NCT06625671 about?
NCT06625671 is a clinical study titled "A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants". A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
What is the current status of trial NCT06625671?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2024-10-04. Estimated completion is 2026-06-05.
What conditions does trial NCT06625671 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).
What interventions are being tested in trial NCT06625671?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), DB-2304 (DRUG).
Who is sponsoring clinical trial NCT06625671?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625671 being conducted?
This trial has 4 study locations across Florida, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus (SLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
-
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
RECRUITING · Phase 1
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RECRUITING
-
Research Accelerated by You Lupus Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.